A RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF FOLFOX PLUS OR MINUS GDC-0449 IN PATIENTS WITH ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) CARCINOMA (NCI 8376)

Trial Profile

A RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY OF FOLFOX PLUS OR MINUS GDC-0449 IN PATIENTS WITH ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) CARCINOMA (NCI 8376)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Vismodegib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top